霉酚酸酯对比无免疫抑制治疗局限性皮肤型系统性硬化症的随机开放标签预试验
MINIMISE-Pilot 是一项随机开放标签预试验,评估霉酚酸酯对比无免疫抑制在局限性皮肤型系统性硬化症(lcSSc)中的可行性,采用事件驱动复合终点。共筛查 53 例、随机 43 例(MMF 组 21 例),因招募低于 60 例预设阈值而提前终止;治疗期间无临床恶化终点事件,MMF 依从性第 1 周为 19 例(95%)完全依从、第 24 周降至 9 例(64%)。
要点
- 招募低于 60 例预设阈值,预试验按计划提前终止。
- 治疗期间未观察到临床恶化终点事件。
- MMF 完全依从比例从第 1 周 95% 降至第 24 周 64%。
核心结论
- 预试验达成可行性评估目标,但因招募不足提前终止,提示在英国 12 个中心、随访期较短的情况下开展该随机前瞻性试验不可行。
研究设计与样本
- 开放标签事件驱动随机预试验,比较 MMF 与无免疫抑制治疗 lcSSc,按 ACA 状态分层,预设 Stop-Go 标准。
- 共筛查 53 例受试者,随机 43 例,其中 MMF 组 21 例。
主要发现
- 招募困难,因入组人数小于 60 例的预设继续阈值而终止试验。
- 治疗期间无临床恶化终点事件发生。
- MMF 依从性总体较高,第 1 周 19 例(95%)完全依从,第 24 周降至 9 例(64%)。
关键数值与推荐
- MINIMISE 复合终点为至 lcSSc 恶化时间,恶化由进行性肺纤维化、肺动脉高压、硬皮病肾危象、心力衰竭、严重肠道受累、主要指端血管并发症或死亡确定。
临床怎么用
- 结果不支持在英国 12 个中心以较短随访期开展 MMF 对比无免疫抑制治疗 lcSSc 的随机前瞻性试验,可为未来研究设计提供参考。
局限性
- 招募低于 60 例预设阈值导致试验提前终止,样本量有限且随访期相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mycophenolate mofetil (MMF) is routinely used in early diffuse cutaneous systemic sclerosis (dcSSc) but not in limited cutaneous (lc)SSc. This may miss an opportunity to slow disease progression. MINIMISE-Pilot tested the feasibility of an open-label event-driven randomised trial of MMF vs no immunosuppression in lcSSc. METHODS: We tested the feasibility of a trial evaluating the impact of MMF on a novel event-driven composite endpoint. The MINIMISE endpoint measures time to worsening of lcSSc determined by progressive lung fibrosis, pulmonary hypertension, scleroderma renal crisis, heart failure, severe gut involvement, major digital vascular complications or death. Prespecified 'Stop-Go' criteria were agreed. Subjects were stratified by ACA status. RESULTS: Recruitment was challenging. A total of 53 subjects were screened and 43 were randomised, 21 to the MMF arm. Since recruitment was <60 participants, MINIMISE-Pilot was terminated based upon the prespecified threshold for continuation. During the treatment period there were no clinical worsening endpoints. Adherence to MMF was generally high, with 19 participants (95%) being 100% adherent at week 1, decreasing to 9 participants (64%) at week 24. CONCLUSION: MINIMISE-Pilot achieved its goal as a feasibility trial, leading to early termination of the study due to low recruitment. The rationale and concept for this study remain very strong. However, our findings suggest that a randomised prospective trial across 12 sites in the UK with relatively short follow-up duration is not feasible. This will inform the design of future studies testing the benefit of MMF in lcSSc. TRIAL REGISTRATION: Eudract (https://eudract.ema.europa.eu/) 2019-004139-21.
引用
- Denton CP, Yee P, Kanitkar M, et al. A randomised open-label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot). Rheumatology (Oxford). 2026. PMID: 41734287. doi:10.1093/rheumatology/keag108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。